These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 28587063)

  • 21. Lysosomal Acid Lipase Activity in Non-alcoholic Fatty Liver Disease as a Novel Diagnostic and Therapeutic Target: A Systematic Literature Review of Current Evidence and Future Directions.
    Bashir A; Duseja A; Verma A; De A; Tiwari P
    J Clin Exp Hepatol; 2022; 12(6):1535-1546. PubMed ID: 36340307
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lysosomal Acid Lipase Activity Is Reduced Both in Cryptogenic Cirrhosis and in Cirrhosis of Known Etiology.
    Vespasiani-Gentilucci U; Gallo P; Piemonte F; Riva E; Porcari A; Vorini F; Tozzi G; Piccioni L; Galati G; De Vincentis A; Carotti S; Morini S; D'Amico J; Angeletti S; Pedone C; Picardi A
    PLoS One; 2016; 11(5):e0156113. PubMed ID: 27219619
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lysosomal acid lipase deficiency allograft recurrence and liver failure- clinical outcomes of 18 liver transplantation patients.
    Bernstein DL; Lobritto S; Iuga A; Remotti H; Schiano T; Fiel MI; Balwani M
    Mol Genet Metab; 2018 May; 124(1):11-19. PubMed ID: 29655841
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Low levels of Lysosomal Acid Lipase (LAL) activity increases necroinflammation in adult patients with biopsy-proven metabolic associated fatty liver disease.
    Thoen RU; Longo L; Neto SC; Álvares-da-Silva MR
    Clin Res Hepatol Gastroenterol; 2021 Nov; 45(6):101638. PubMed ID: 33662773
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Clinical Difference in the Platelet Counts between Liver Cirrhosis with Nonalcoholic Fatty Liver Disease and Hepatitis C Virus.
    Ikarashi Y; Kodama K; Taniai M; Hashimoto E; Tokushige K
    Intern Med; 2018 Apr; 57(8):1065-1070. PubMed ID: 29269684
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Opening a window on lysosomal acid lipase deficiency: Biochemical, molecular, and epidemiological insights.
    Cappuccio G; Donti TR; Hubert L; Sun Q; Elsea SH
    J Inherit Metab Dis; 2019 May; 42(3):509-518. PubMed ID: 30684275
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lysosomal acid lipase deficiency: Expanding differential diagnosis.
    Valayannopoulos V; Mengel E; Brassier A; Grabowski G
    Mol Genet Metab; 2017; 120(1-2):62-66. PubMed ID: 27876313
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sebelipase alfa in children and adults with lysosomal acid lipase deficiency: Final results of the ARISE study.
    Burton BK; Feillet F; Furuya KN; Marulkar S; Balwani M
    J Hepatol; 2022 Mar; 76(3):577-587. PubMed ID: 34774639
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Liver disease and dyslipidemia as a manifestation of lysosomal acid lipase deficiency (LAL-D). Clinical and diagnostic aspects, and a new treatment. An update.
    Bay L; Canero Velasco C; Ciocca M; Cotti A; Cuarterolo M; Fainboim A; Fassio E; Galoppo M; Pinero F; Rozenfeld P
    Arch Argent Pediatr; 2017 Jun; 115(3):287-293. PubMed ID: 28504497
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A practical fluorometric assay method to measure lysosomal acid lipase activity in dried blood spots for the screening of cholesteryl ester storage disease and Wolman disease.
    Dairaku T; Iwamoto T; Nishimura M; Endo M; Ohashi T; Eto Y
    Mol Genet Metab; 2014 Feb; 111(2):193-6. PubMed ID: 24295952
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Extended use of a selective inhibitor of acid lipase for the diagnosis of Wolman disease and cholesteryl ester storage disease.
    Civallero G; De Mari J; Bittar C; Burin M; Giugliani R
    Gene; 2014 Apr; 539(1):154-6. PubMed ID: 24508470
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical Features of Lysosomal Acid Lipase Deficiency.
    Burton BK; Deegan PB; Enns GM; Guardamagna O; Horslen S; Hovingh GK; Lobritto SJ; Malinova V; McLin VA; Raiman J; Di Rocco M; Santra S; Sharma R; Sykut-Cegielska J; Whitley CB; Eckert S; Valayannopoulos V; Quinn AG
    J Pediatr Gastroenterol Nutr; 2015 Dec; 61(6):619-25. PubMed ID: 26252914
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lysosomal Acid Lipase: Can it be a New Non-Invasive Serum Biomarker of Cryptogenic Liver Fibrosis and Cirrhosis?
    Gravito-Soares M; Gravito-Soares E; Gomes D; Tome L
    Ann Hepatol; 2019; 18(1):78-88. PubMed ID: 31113613
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sebelipase alfa improves atherogenic biomarkers in adults and children with lysosomal acid lipase deficiency.
    Wilson DP; Friedman M; Marulkar S; Hamby T; Bruckert E
    J Clin Lipidol; 2018; 12(3):604-614. PubMed ID: 29628368
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Form of Metabolic-Associated Fatty Liver Disease Associated with a Novel LIPA Variant.
    Anushiravani A; Jafari Khamirani H; Mohamadkhani A; Mani A; Dianatpour M; Malekzadeh R
    Arch Iran Med; 2023 Feb; 26(2):86-91. PubMed ID: 37543928
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel LIPA mutations in Mexican siblings with lysosomal acid lipase deficiency.
    Santillán-Hernández Y; Almanza-Miranda E; Xin WW; Goss K; Vera-Loaiza A; Gorráez-de la Mora MT; Piña-Aguilar RE
    World J Gastroenterol; 2015 Jan; 21(3):1001-8. PubMed ID: 25624737
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification and metabolic profiling of patients with lysosomal acid lipase deficiency.
    Pullinger CR; Stock EO; Movsesyan I; Malloy MJ; Frost PH; Tripuraneni R; Quinn AG; Ishida BY; Schaefer EJ; Asztalos BF; Kane JP
    J Clin Lipidol; 2015; 9(5):716-26.e1. PubMed ID: 26350820
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lysosomal Acid Lipase: From Cellular Lipid Handler to Immunometabolic Target.
    Gomaraschi M; Bonacina F; Norata GD
    Trends Pharmacol Sci; 2019 Feb; 40(2):104-115. PubMed ID: 30665623
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Could lysosomal acid lipase enzyme activity be used for clinical follow-up in cryptogenic cirrhosis?
    Köse E; Çağatay E; Yaraş T; Kısa PT; Güler S; Gülten ZA; Akarsu M; Oktay Y; Kayalı HA; Arslan N
    Turk J Med Sci; 2022 Aug; 52(4):1075-1084. PubMed ID: 36326406
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Lysosomal acid lipase deficiency (LAL-D) : Diagnostic and therapeutic options in an underdiagnosed disease].
    Synoracki S; Kathemann S; Schmid KW; Jastrow H; Baba HA
    Pathologe; 2018 May; 39(3):249-254. PubMed ID: 29234937
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.